Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582020 | 0.90 | EGLN1 (0.41) | EGLN1HIF1A | |
| SCHEMBL2582713 | 0.88 | EGLN1 (0.51) | EGLN1HIF1A | |
| SCHEMBL2582916 | 0.88 | L3MBTL1 (0.44) | EGLN1HIF1A | |
| SCHEMBL2582050 | 0.88 | EGLN1 (0.40) | EGLN1HIF1A | |
| SCHEMBL2586250 | 0.81 | EGLN1 (0.39) | EGLN1HIF1A | |
| SCHEMBL2579266 | 0.81 | HIF1A (0.48) | EGLN1HIF1A | |
| SCHEMBL2577065 | 0.79 | EGLN1 (0.45) | EGLN1HIF1A | |
| SCHEMBL3824532 | 0.79 | EGLN1 (0.39) | EGLN1HIF1A | |
| SCHEMBL2587868 | 0.79 | HIF1A (0.51) | EGLN1HIF1A | |
| SCHEMBL2578471 | 0.78 | EGLN1 (0.52) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170175-A1 | COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN | BAUSCH & LOMB INCORPORATED (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-2097416-B1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048892-B2 | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2011-11-01 | — | — | US | disclosed |
| EP-2097416-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | Amgen, Inc (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2056799-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | Bausch & Lomb Incorporated (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
| EP-2051710-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2051736-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | Bausch & Lomb Incorporated (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076425-A1 | AZAQUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF | AMGEN INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008027796-A2 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING GLAUCOMA OR PROGRESSION THEREOF | BAUSCH & LOMB INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008021729-A2 | COMPOSITIONS AND METHODS FOR TREATING, REDUCING, AMELIORATING, OR ALLEVIATING POSTERIOR-SEGMENT OPHTHALMIC DISEASES | BAUSCH & LOMB INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008005686-A2 | COMPOSITIONS COMPRISING A DISSOCIATED GLUCOCORTICOID RECEPTOR AGONIST AND AN IMMUNOSUPPRESSIVE AGENT FOR TREATING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111806-A1 | Azaquinolone based compounds exhibiting prolyl hydroxylase Inhibitory activity, compositions, and uses thereof | EGLN3, EGLN2, HIF1AN | EGLN1 5/4885HIF1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.